What is the 13F Pro Quality Score for GLSI?

13F Pro ranks Greenwich LifeSciences, Inc. (GLSI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GLSI's current score at https://13fpro.ai/research/GLSI (free sign-up required for the full ranking).

Where does 13F Pro source GLSI data?

All Greenwich LifeSciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Greenwich LifeSciences, Inc. files with the SEC under CIK 1799788. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GLSI in?

Greenwich LifeSciences, Inc. (GLSI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GLSI research updated on 13F Pro?

GLSI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Greenwich LifeSciences, Inc.(GLSI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1799788 GLSI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GLSI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Greenwich LifeSciences, Inc. (GLSI), a Healthcare sector company. GLSI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Greenwich LifeSciences, Inc. reports net income of $-5.7M, free cash flow of $-4.7M. Top institutional holders of GLSI by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. GLSI trades on the Nasdaq exchange and files with the SEC under CIK 1799788. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLSI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Greenwich LifeSciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.7M

Free Cash Flow

Q1 2026

$-4.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-11.2% YoY

$-19.4MFY 2025

FY22 $-7.8MFY23 $-8.9MFY24 $-17.4MFY25 $-19.4M

Operating Income

-10.3% YoY

$-19.4MFY 2025

FY22 $-8.0MFY23 $-9.3MFY24 $-17.6MFY25 $-19.4M

EPS (Diluted)

-6.7% YoY

$-1.43FY 2025

FY22 $-0.61FY23 $-0.69FY24 $-1.34FY25 $-1.43

Total Assets

+50.9% YoY

$6.2MFY 2025

FY22 $13.5MFY23 $7.0MFY24 $4.1MFY25 $6.2M

Op. Cash Flow

-36.4% YoY

$-9.9MFY 2025

FY22 $-6.2MFY23 $-6.5MFY24 $-7.3MFY25 $-9.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-19.4M -11.2%	$-17.4M -95.8%	$-8.9M -13.6%	$-7.8M -71.2%	$-4.6M -145.3%	$-1.9M
Operating Income	$-19.4M -10.3%	$-17.6M -89.1%	$-9.3M -16.0%	$-8.0M -74.9%	$-4.6M -146.7%	$-1.9M
EPS (Diluted)	$-1.43 -6.7%	$-1.34 -94.2%	$-0.69 -13.1%	$-0.61	—	—
Total Assets	$6.2M +50.9%	$4.1M -41.5%	$7.0M -48.1%	$13.5M -50.5%	$27.2M -5.1%	$28.7M
Operating Cash Flow	$-9.9M -36.4%	$-7.3M -12.2%	$-6.5M -4.5%	$-6.2M -44.5%	$-4.3M -272.2%	$-1.2M

AI Insight: GLSI Financial Trends

Greenwich LifeSciences remains pre-revenue with persistent operating losses and equity near zero; cash burn accelerating.

• Operating cash flow deteriorated from -$1M in Q2 2024 to -$5M in Q1 2026, a five-fold increase in quarterly burn.

• Equity collapsed from $6M in Q2 2024 to $0M in Q4 2025, then recovered to $5M in Q1 2026 — likely capital raise.

• No revenue reported across all eight quarters; net losses ranged $3M–$8M per quarter with no improvement trajectory.

⚠ Operating cash burn jumped $2M from Q4 2025 to Q1 2026; runway sustainability unclear without disclosed cash balance.

⚠ Q1 2026 equity recovery signals dilutive financing; balance sheet remains under severe pressure.

AI Insight: GLSI Ratio Trends

Insufficient financial data to establish trend analysis — only one ROE reading (-177.5% in Q2 2024) available across nine quarters.

• Q2 2024 ROE of -177.5% reflects significant net losses; no subsequent quarterly profitability metrics disclosed.

⚠ Complete absence of operating margin, NPM, ROIC, and leverage data prevents assessment of operational efficiency or capital structure trends.

⚠ Return to profitability and sustainable positive ROE/ROA/ROIC generation critical milestones for investor confidence.

Get alerted when GLSI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Greenwich LifeSciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GLSI

BlackRock, Inc.
$10.4M433,860 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.2M298,266 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.7M155,466 sh
STATE STREET CORP
$3.2M133,875 sh
Nuveen, LLC
$2.1M88,717 sh
NORTHERN TRUST CORP
$1.8M75,125 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.4M58,911 sh
Bank of New York Mellon Corp
$1.1M46,523 sh
VANGUARD FIDUCIARY TRUST CO
$1.1M44,908 sh
Russell Investments Group, Ltd.
$953.6K39,697 sh

Fund	Value	Shares
BlackRock, Inc.	$10.4M	433,860
VANGUARD CAPITAL MANAGEMENT LLC	$7.2M	298,266
GEODE CAPITAL MANAGEMENT, LLC	$3.7M	155,466
STATE STREET CORP	$3.2M	133,875
Nuveen, LLC	$2.1M	88,717
NORTHERN TRUST CORP	$1.8M	75,125
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.4M	58,911
Bank of New York Mellon Corp	$1.1M	46,523
VANGUARD FIDUCIARY TRUST CO	$1.1M	44,908
Russell Investments Group, Ltd.	$953.6K	39,697

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GLSI on your watchlist

Track score changes the day Greenwich LifeSciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GLSI a good stock to buy?

13F Pro's AI-powered analysis of Greenwich LifeSciences, Inc. (GLSI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GLSI are available on the GLSI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GLSI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GLSI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Greenwich LifeSciences, Inc.'s investment landscape.